Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

@article{Larosa2005IntensiveLL,
  title={Intensive lipid lowering with atorvastatin in patients with stable coronary disease.},
  author={John C Larosa and Scott M. Grundy and David D. Waters and Charles L. Shear and Philip John Barter and J-C. Fruchart and Antonio M. Jr. Gotto and Heiner Greten and John J. P. Kastelein and James Shepherd and Nanette Kass Wenger},
  journal={The New England journal of medicine},
  year={2005},
  volume={352 14},
  pages={
          1425-35
        }
}
View on PubMed
doi.org
2,083 Citations
Highly Influential Citations
87
Background Citations
189
Methods Citations
36
Results Citations
26

2,083 Citations

Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes
TLDR
Among patients with clinically evident CHD and diabetes, intensive therapy with atorvastatin 80 mg significantly reduced the rate of major cardiovascular events by 25% compared with at ORVastatin 10 mg.
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
TLDR
When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes, and lowering LDL cholesterol to levels below previous targets provided additional benefit.
Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol.
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.
TLDR
Patients with diabetes, stable coronary artery disease, and mild to moderate CKD experience marked reduction in cardiovascular events with intensive lipid lowering, in contrast to previous observations in patients with diabetes and end-stage renal disease.
Combination therapy in dyslipidemia: where are we now?
Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol
TLDR
Evidence is provided that higher intensity statins are beneficial for cardiovascular outcomes in patients with stable CAD and very low LDL-C, and statins equivalent to or stronger than atorvastatin 20 mg are more effective than lower intensitystatins.
Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.
TLDR
Most patients with STEMI are prescribed statin therapy at discharge, and despite this, the target LDL-C is attained in a minority of the patients due to suboptimal statin dosing, which emphasizes the opportunities to improve outcomes of STEMI patients with evidence-based therapies.
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.
Effect of two intensive statin regimens on progression of coronary disease.
TLDR
Maximal doses of rosuVastatin and atorvastatin resulted in significant regression of coronary atherosclerosis, with a low incidence of laboratory abnormalities and cardiovascular events.
...
...

References

SHOWING 1-10 OF 23 REFERENCES
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
TLDR
Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.
TLDR
This American College of Cardiology/American Heart Association/National Heart, Lung and Blood Institute/ACC/AHA/NHLBI Clinical Advisory is intended to summarize for professionals the current understanding of statin use, focused on myopathy, and to provide updated recommendations for the appropriate use of statins, including cautions, contraindications, and safety monitoring for statin therapy.
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
TLDR
The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL, and confirm that older persons benefit from therapeutic lowering of LDL-C.
European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts).
  • G. De Backer, E. Ambrosioni, D. Wood
  • Medicine
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology
  • 2003
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
F RANK M. S ACKS , M.D., M ARC A. P FEFFER , M.D., P H .D., L EMUEL A. M OYE , M.D., P H .D., J EAN L. R OULEAU , M.D., J OHN D. R UTHERFORD , M.D., T HOMAS G. C OLE , P H .D., L ISA B ROWN , M.P.H.,…
European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.
...
...